05/25/22 8:00 AMNasdaq : PHAT low floatPhathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive EsophagitisPhathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted forRHEA-AIpositive
05/24/22 12:15 PMNasdaq : PHAT low floatPhathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022Results from an investigational Phase 3 PHALCON-EE trial demonstrating superior healing at week 2 in patients with LA Grade C/D (moderate-to-severe) erosive esophagitis and superior maintenance of healing at week 24 in all patients with vonoprazan versus lansoprazole shared in oral presentation 1RHEA-AIneutral
05/17/22 8:01 AMNasdaq : PHAT conferenceslow floatPhathom Pharmaceuticals to Present Data at DDW 2022 Annual MeetingNew investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori ( H. pylori) infection Phathom research recognized with multiple “posters of distinction” by AmericanRHEA-AIvery positive
05/10/22 8:00 AMNasdaq : PHAT low floatPhathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business UpdatesU.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H. pylori infection in adults Up to $260 million revenue interest financing agreement strengthens balanceRHEA-AIvery positive
05/04/22 8:01 AMNasdaq : PHAT low floatPhathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive CapitalUpfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE) Provides capital for launch of vonoprazan in H. pylori and EE, if approved, in addition to Phase 3 program in non-erosive reflux disease (NERD) TotalRHEA-AIvery positive
05/03/22 5:40 PMNasdaq : PHAT fda approvallow floatPhathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in AdultsVOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy in the overall patient population of the pivotal Phase 3 trial 1 VOQUEZNA treatmentRHEA-AIneutral
04/26/22 8:00 AMNasdaq : PHAT managementlow floatPhathom Pharmaceuticals Appoints Frank Karbe to its Board of DirectorsPhathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr.RHEA-AIneutral
04/01/22 8:01 AMNasdaq : PHAT conferenceslow floatPhathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare ConferencePhathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team willRHEA-AIneutral
03/22/22 8:02 AMNasdaq : PHAT managementlow floatPhathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business OfficerPhathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to theRHEA-AIneutral
03/16/22 5:00 AMNasdaq : PHAT, ARQT low floatFrazier Life Sciences Closes $987 Million Venture Fund to Invest in Companies Developing Novel BiopharmaceuticalsFrazier Life Sciences announced today the closing of Frazier Life Sciences XI, L.P., exceeding its target of $800 million and raising more than $987 million in capital commitments in an oversubscribed fundraise. FLS XI will be led by Managing Partners Patrick Heron and James Topper and General Partner Dan Estes, who have been with Frazier for 24, 20, and 12 years...RHEA-AIneutral